-transparent.png){kind=logo}
BACKGROUND Results of readily available clinical laboratory tests in patients with chronic fatigue syndrome were compared with results in healthy control subjects. METHODS Cases consisted of all 579 patients who met either the Centers for Disease Control and Prevention, Atlanta, Ga, British, or Australian case definition for chronic fatigue syndrome. They were from chronic fatigue clinics in Boston, Mass, and Seattle, Wash. Control subjects consisted of 147 blood donors who denied chronic fatigue. Outcome measures were the results of 18 clinical laboratory tests. RESULTS Age- and sex-adjusted odds ratios of abnormal results, comparing cases with control subjects, were as follows: circulating immune complexes, 26.5 (95% confidence interval [CI] 3.4-206), atypical lymphocytosis, 11.4 (95% CI, 1.4-94); elevated immunoglobulin G, 8.5 (95% CI, 2.0-37); elevated alkaline phosphatase, 4.2 (95% CI, 1.6-11); elevated total cholesterol, 2.1 (95% CI, 1.2-3.4); and elevated lactic dehydrogenase, 0.30 (95% CI, 0.16-0.56). Also, antinuclear antibodies were detected in 15% of cases vs 0% in the control subjects. The results of these tests were generally comparable for the cases from Seattle and Boston. Although these tests served to discriminate the population of patients from healthy control subjects, at the individual level they were not as useful. CONCLUSIONS Patients with chronic fatigue syndrome who were located in two geographically distant areas had abnormalities in the results of several readily available clinical laboratory tests compared with healthy control subjects. The immunologic abnormalities are in accord with a growing body of evidence suggesting chronic, low-level activation of the immune system in chronic fatigue syndrome. While each of these laboratory findings supports the diagnosis of chronic fatigue syndrome, each lacks sufficient sensitivity to be a diagnostic test. Furthermore, the specificity of these findings relative to other organic and psychiatric conditions that can produce fatigue remains to be established.
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
June 1995,
Archives of internal medicine,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
January 1991,
Reviews of infectious diseases,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
November 1992,
Nihon rinsho. Japanese journal of clinical medicine,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
August 1996,
Australian and New Zealand journal of medicine,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
June 1997,
Australian and New Zealand journal of medicine,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
January 1995,
Acta oto-laryngologica,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
January 1996,
Scandinavian journal of infectious diseases,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
March 2012,
Journal of dermatological case reports,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
September 1990,
The Journal of infection,
D W Bates, and
D Buchwald, and
J Lee, and
P Kith, and
T Doolittle, and
C Rutherford, and
W H Churchill, and
P H Schur, and
M Wener, and
D Wybenga
January 1991,
Reviews of infectious diseases,
